NEW YORK, Sept 28 –German bioinformatics company Lion Bioscience (Neuer Markt: LIO, Nasdaq: LEON) said Thursday its first quarter fiscal 2001 net losses increased to 14.04 million euros ($12.4 million), or 1.84 euros per share, compared with net losses of 3.31 million euros, or 0.60 euro a share, in the year ago period.

The first-quarter 2001 results include a non-cash compensation expense of 8.7 million euros from the conversion of preferred shares to ordinary shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.